Concomitant medication of psychoses in a lifetime perspective

✍ Scribed by Maria Vares; Peter Saetre; Pontus Strålin; Sten Levander; Eva Lindström; Erik G. Jönsson

• Book ID: 102261456
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 141 KB
• Volume: 26
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.1209

✦ Synopsis

Objective

Patients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness.

Methods

A retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders.

Results

Benzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics.

Conclusions

Most psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright © 2011 John Wiley & Sons, Ltd.